Requires prescription containers for opioid medications to have a red cap top and a printed warning

2025 Regular Session Introduced by Jake Ashby and 3 co-sponsors

Opioid prescription containers must use red caps and display a printed warning to improve safety, guiding patients, pharmacies, prescribers and manufacturers toward safer handling.

REFERRED TO HEALTH

Summary: Senate Bill S 5299

Title

Requires prescription containers for opioid medications to have a red cap top and a printed warning

Status and process

Introduced: February 20, 2025

Current status: Referred to Health

Legislative actions: On February 20, 2025, the bill was referred to the Health committee (listed twice in the provided record)

Next steps: If the Health committee advances the bill, it would move to the floor for debate and a vote, with potential amendments. Tracking continues to be through the Health committee and floor proceedings.

Purpose and intent

The bill aims to enhance safety and awareness around opioid medications by imposing packaging requirements. Specifically, it mandates that prescription containers for opioids use a red cap and include a printed warning. The stated goal is to reduce misuse and promote safer handling of opioid prescriptions, contributing to public health and safety objectives.

Key provisions (as described)

Packaging change: All prescription containers for opioid medications must have a red cap top.

Warning label: A printed warning must appear on the prescription container.

Wording and implementation details: The summary provided does not specify the exact wording of the warning or the effective date, and it does not outline a phased-in timeline. Implementation specifics would presumably be addressed in the bill's text or in committee amendments.

Affected parties and impacts

Patients: Opioid recipients would encounter uniform red caps and visible warnings, which may influence consumption behavior and awareness of risks.

Pharmacists and pharmacies: Pharmacy packaging processes would need to accommodate the red cap requirement and ensure printed warnings are applied.

Prescribers and suppliers: Manufacturers and distributors of opioid medications may need to adjust packaging to comply with the new standard.

Manufacturers: Potential compliance and labeling costs associated with changing packaging design.

Related legislation

Related Bill: S 6111 (prior-session) — noted as a related bill, suggesting similar or related safety packaging objectives in a prior session.

Sponsor information

Primary sponsor: Jake Ashby

Cosponsors: George Borrello, William Weber, Steve Rhoads

Practical considerations

Public health rationale: Aligns with broader efforts to reduce opioid misuse and improve patient safety through clearer warnings and standardized packaging.

Procedural considerations: As a protocol, the bill would require committee review, potential hearings, and votes before any enactment. Stakeholders (pharmacists, insurers, manufacturers, patient groups) may seek data on cost, feasibility, and effectiveness during consideration.

Notes

No specific fiscal impact, enforcement mechanism, or effective date is provided in the available summary. Readers seeking more detail should review the full bill text and any fiscal notes or amendments discussed in committee.